The ASCO Post

🩺 Could AI bring more care directly to patients? At Cleveland Clinic’s A.I. Summit, leaders discussed AI’s potential to identify disease earlier, expand access, support remote monitoring, and extend care beyond traditional settings. 🔗 https://ow.ly/S8It50ZPTcj

🆕 HARMONi-2 data show an OS benefit with ivonescimab vs pembrolizumab in PD-L1+ advanced NSCLC. ➡️ Benefits particularly notable among patients with PD-L1 TPS ≥50% (HR = 0.58) 🗣️ Presented by Caicun Zhou, MD, PhD 🔗 https://ow.ly/hvZ150ZPCIt

💻 ASCO AI: For healthcare AI, technical performance may not translate into better patient care. Among 34 authorized devices linked to prospective trials, 82.4% of trials relied on surrogate measures as endpoints rather than patient-centered outcomes. 🔗 https://ow.ly/h1Nx50ZPCGK

🩸Five-year OPTIMUM data show sustained PFS and OS improvements with intensive, risk-adapted extended therapy in newly diagnosed high-risk #ultiple Myeloma. ➡️ Median PFS and OS were not reached ▪️Martin F. Kaiser, MD | The Lancet Oncology 🔗 https://ow.ly/sQjI50ZPCBn

🫁 The U.S. Food and Drug Administration has approved updated labeling for taletrectinib (Ibtrozi) in advanced ROS1+ NSCLC, reflecting a median duration of response of 49.7 months in TKI-naive patients from the TRUST-I trial. Learn more about the updated label ➡️ https://ow.ly/Ueht50ZPCEm

🧬 Early- and average-onset metastatic Colorectal Cancer shared a similar genomic backbone, but MYC alterations were more frequent in early-onset disease, and several other alterations increased with younger age. 🔹 Seung Tae Kim, MD, PhD 🔗 https://ow.ly/kfnc50ZOsAs

💻 #ASCOAI: ChatGPT for Healthcare can now connect with Epic allowing clinicians to query patient charts for medication changes, lab results & unresolved issues, with supporting evidence from patients’ records. Learn more ➡️ https://ow.ly/7PUe50ZNzag

🆕 research suggests inherited genetics may help classify therapy-related myeloid neoplasms and identify patients who could benefit from personalized risk assessment, genetic counseling & closer monitoring. 🔹Francesc Solé, PhD | Blood Advances https://ow.ly/yuNt50ZNz9y

🚺 As Cervical Cancer nonscreening increased, regional- & distant-stage disease among women aged 30–64 each rose by >2% annually after 2017. ➡️ Researchers call for targeted strategies to improve screening uptake ▪️Kalyani Sonawane, PhD | JAMA Network Open https://ow.ly/L8Z450ZLBy5

🫀Could mammograms offer insights beyond Breast Cancer? An AI model showed potential to identify hypertension, ischemic heart disease, and cerebrovascular accident without additional imaging. 🗣️Presented by Viana Copeland, MBBS at #ESCCongress 🔗 https://ow.ly/Qeme50ZLByx

🧬Anastrozole + palbociclib + trastuzumab + pertuzumab showed clinical benifits as a chemotherapy-free first-line approach for patients with HR+/HER2+ metastatic Breast Cancer in the phase I/II ASPIRE trial. 🔹 Amy Tiersten, MD 🔗 https://ow.ly/V9nU50ZHLaB

🩸Can blood-based screening detect early colorectal cancer? At ASCO Breakthrough, researchers reported combining cfDNA fragmentomics with methylation markers improved sensitivity for precancerous lesions. 🗣️ Presented by Thi Tuong Vi Van, BSc https://ow.ly/FjqT50ZHLbt

🚹 In NRG-GU005, SBRT improved bowel-related quality of life vs moderately hypofractionated IMRT for favorable intermediate-risk #ProstateCancer. ➡️ Did not improve urinary outcomes or cancer control ▪️ Howard M. Sandler, MD, MS, | JAMA 🔗 https://ow.ly/a63X50ZHF7m

🥼 High patient volumes, limited resources, workforce shortages, and academic pressures can compound burnout for mid-career oncologists in LMIC regions. Dr. Muhammad Rafiqul Islam provides navigation strategies in this commentary. Learn more here 👉 https://ow.ly/Nb2g50ZHhRp

🖥️ ASCO AI: HemaGuide, a locally deployable LLM agent, turns clinical documentation into treatment recommendations with traceable rationales. Across external validation, it achieved 81.8% concordance with tumor board decisions in hematologic malignancies. https://ow.ly/q8mE50ZHF5K

🖥️ #ASCOAI: Clinical records, imaging, pathology, and molecular profiles generate vast amounts of oncology data, but much remains fragmented. Arsela Prelaj, MD, PhD, discusses how the “Leave No Data Behind” paradigm models could help bring these data together. 🔗 https://ow.ly/6IMw50ZGG9O

💉#ASCOAI: A phase III trial has reported positive results for an individualized neoantigen therapy combo designed with a “deterministic machine learning bioinformatic algorithm.” Intismeran + pembrolizumab improved RFS and DMFS in resected melanoma. 🔗 https://ow.ly/1nVt50ZHL7W

🚹 Nearly 40% of men with Prostate Cancer had newly documented metabolic syndrome within 12 months of starting ADT + ARPI. ➡️ Highlights the importance of early metabolic monitoring 🔹Drs. Amy L. Shaver & Grace Lu-Yao | JAMA Oncology 🔗 https://ow.ly/x3O950ZGG86

🔬 Could immune adaptation contribute to exceptional longevity? Researchers found an expansion of CD4 cytotoxic T cells among supercentenarians, suggesting the immune system may continue adapting in advanced age. ▪️Kosuke Hashimoto, PhD | @cellreports.bsky.social https://ow.ly/2VyU50ZGG76

🩸As survival after Hodgkin Lymphoma improves, long-term health risks remain. New findings highlight cardiovascular disease, secondary cancers, other chronic conditions as priorities for survivorship care. 🔹Drs. Valcarcel & Castillo | JAMA Network Open https://ow.ly/A4oY50ZGw4v

🖥️ One model, 348 diseases. Researchers developed a Bayesian machine learning framework combining longitudinal EHR and genetic data to predict future disease risk and uncover patterns of disease co-occurrence. Read the full article ➡️ https://ow.ly/FzUx50ZEWsA

🥤Daily consumption of sugar-sweetened beverages was associated with an increased risk of developing Gastric Cancer. ➡️ Artificially sweetened beverages were not associated with increased risk ▪️Andrew T. Chan, MD, MPH 🔗 https://ow.ly/wipF50ZEWro

Excess adiposity was linked to a twofold higher risk of vertebral fracture progression in patients with early #BreastCancer receiving aromatase inhibitors. 💪 Higher muscle mass was protective. ▪️Deborah Cosentini, MD | JAMA Network Open 🔗 https://ow.ly/xl4J50ZEWpX

🏘️ The ACS Commission on Cancer has introduced a Rural Cancer Program Accreditation pathway tailored to hospitals in rural counties, aiming to expand access to coordinated, high-quality cancer care closer to home. Learn more 👉 https://ow.ly/JKZN50Zzxvz

📱 A technology-enabled education program nearly tripled skinc ancer screening among HCT survivors, who face elevated long-term risk. ➡️ Outreach to survivors and PCPs could close gaps in cancer survivorship care 🔸Saro Armenian, DO, MPH | JNCCN 🔗 https://ow.ly/Ck4I50Zzxwn

🧬 Decade-long NIH-funded research has created 665 patient-derived tumor models for 25 cancer types. The Human Cancer Models Initiative links models with molecular, clinical data to help researchers study cancer biology & advance precision oncology. 🔗 https://ow.ly/GzxK50Zzxth

🧬A novel HER2-directed antibody-drug conjugate delivered PFS benefit in HER2+ metastatic Breast Cancer In HORIZON-Breast01, trastuzumab rezetecan reduced risk of progression/death by 78% vs pyrotinib + capecitabine. ▪️Erwei Song, MD | The Lancet Oncology 🔗 https://ow.ly/6wCY50ZyGzw

🌏 Nearly 4 in 10 cancer cases worldwide are linked to preventable risk factors. The WHO Global Status Report on Cancer 2026 highlights persistent inequities in prevention, diagnosis, treatment, & supportive care. ➡️ Calls for stronger global action 🔗 https://ow.ly/IwjN50ZyGAt

💻 ASCO AI: MIRA and AMIE move #AI beyond answering clinical questions toward managing episodes of care. Two Nature studies simulating clinical reasoning and patient care suggest agentic AI could support EHR workflows and longitudinal care. 🔗 https://ow.ly/8jIf50ZwLKB

🧬 Ultra low–dose IL-10–expressing CAR T-cell therapy (META 10-19) showed encouraging activity in relapsed/refractory DLBCL, with a 92.3% overall response rate and 84.6% complete remission rate in a phase I trial. ▪️Drs. He Huang & Xingbing Wang | JAMA Oncology https://ow.ly/buqe50Zxyvg

🖥️ Quantum computing may help advance precision #immunooncology. A new quantum machine learning framework (Q-CHIPP) improved prediction of antigen presentation and immunotherapy response vs traditional methods. ▪️Tyler J. Alban, PhD Learn more ➡️ https://ow.ly/mNEk50ZxyvT

🔬Phase 3️⃣ KEYNOTE-B15/EV-304 trial: Perioperative enfortumab vedotin + pembrolizumab improved event-free survival, overall survival, and pathologic complete response vs cisplatin + gemcitabine in muscle-invasive bladder cancer. 🔹 Matthew D. Galsky, MD 🔗 https://ow.ly/ePbl50ZwLIT

🖥️ ASCO AI: From diagnosis to treatment selection and clinical trial matching, AI could support decision-making across the cancer care journey. Experts at ASCOBT 2026 discuss what's needed to make AI work in real-world oncology. Learn more ➡️ https://ow.ly/ezrQ50ZwAir

🖥️ AI may help personalize neoadjuvant treatment for locally advanced rectal cancer. Patients with high tumor cell density had improved survival with irinotecan-intensified chemoradiotherapy vs those with low density. 🔹 Dr. Maria A. Hawkins 🔗 https://ow.ly/jpVm50ZwLH3

💰New American Cancer Society research quantifies the economic burden of cancer in older adults, reinforcing the importance of prevention, early detection, and affordable access to care to reduce both financial hardship and advanced disease costs. Learn more ➡️ https://ow.ly/K8Ws50ZwLFC

💉High-dose chemotherapy then autologous stem cell transplantation improved OS vs nonmyeloablative consolidation in patients with primary CNS lymphoma who responded to MATRix induction. ➡️ Results from phase III MATRix/IELSG43 trial 🔹 Gerald Illerhaus, MD https://ow.ly/mKfM50ZwAiK

💻 #ASCOAI: @anthropicai.bsky.social is making a major push into health care. New initiatives include Claude Science, an #AI platform for scientific research, an internal rare disease drug discovery program, and grants supporting rare disease research. Learn more ➡️ https://ow.ly/eklU50Ztwg6

🏥 How a cancer is diagnosed may matter as much as the diagnosis itself. A new study found patients diagnosed during an emergency department visit had significantly higher mortality across 16 cancer types. ▪️Dr. Georgios Lyratzopoulos 🔗 https://ow.ly/xvXR50Ztvyv

Meta-analysis highlights differences in BTK inhibitor safety with 2nd-generation BTK inhibitors vs ibrutinib: 🔹 Lower risk of atrial fibrillation 🔹 Fewer cardiac events 🔹 Less treatment discontinuation 👨‍⚕️ Moaath Mustafa Ali, MD, MPH https://ow.ly/AZFu50ZqNFw

🏆 Association for Molecular Pathology honored Elaine S. Jaffe, MD, with its 2026 Award for Excellence in Molecular Diagnostics. Her work defining the molecular basis of #ymphomas has influenced decades of clinical practice, research and disease classification. Read more 👉 https://ow.ly/97t250ZspaN

🖥️ ASCO AI: A perfect AI match doesn't guarantee a patient gets on a clinical trial Charles Jiang, MD, examines the real-world workflow, protocol, and operational barriers that continue to limit trial participation. Read the commentary👉 https://ow.ly/KTRW50ZqNGS

🩸 ctDNA continues to show promise as a clinical decision-making tool 🆕 GALAXY data: molecular residual disease status may help identify which patients benefit from adjuvant chemotherapy after resection of colorectal cancer liver metastases. 🔗 https://ow.ly/MmRk50ZqNEl

🌎 Emerging evidence suggests air pollution, tobacco smoke, and pesticide exposure may affect long-term outcomes for childhood cancer survivors. In this interview, Omar Shakeel, MD, details why environmental health should be part of survivorship care. 🔗 https://ow.ly/7UAi50ZqNCs

🖥️ ASCO AI: Machine learning ➕ 3D bioprinting ➕ label-free imaging A new protocol enables high-throughput drug response profiling in tumor organoids, helping identify treatment response patterns that could support precision oncology. Learn more ➡️ https://ow.ly/YGhM50ZqcS3

20-year follow-up from the phase III EORTC 22922/10925 trial found: ➡️ IM-MS nodal irradiation reduced #breastcancer mortality in node-negative disease ➡️ Did not improve non–breast cancer mortality 🔸Philip Poortmans, PhD | The Lancet Oncology Learn more: https://ow.ly/Kv8v50Zq2v9

🤝 The future of AI in dermatology may be collaborative New data found a modern #AI model outperformed less experienced clinicians at diagnosing #SkinCancer but did not outperform expert dermatologists. 🔹Julien Anriot, MD | JAMA Dermatology 🔗 https://ow.ly/2Uou50Zq2u8

🧠 Phase 3️⃣ INTRAGO-II results: Adding intraoperative radiotherapy to surgery did not improve PFS or OS in patients with newly diagnosed glioblastoma, challenging the role of further local dose escalation. 🔹 Frank A. Giordano, MD 🔗 https://ow.ly/URuy50ZoSch

🌎 The latest American Cancer Society Global Cancer Statistics report provides a comprehensive look at cancer incidence, mortality, and trends in 186 countries. The report highlights: ➡️ Rising global burden ➡️ Persistent disparities ➡️ Prevention opportunities https://ow.ly/eZHc50ZoSbR

🖥️ #ASCOAI: New legislation aims to accelerate pediatric cancer research through AI. The AI for Kids With Cancer Act would strengthen data sharing, expand clinical trial access, and support AI innovation to improve outcomes for children with cancer. 🔗 https://ow.ly/h8hy50ZohKf

🫀 Cardio-oncology begins with prevention. A global analysis found smoking and alcohol use were shared modifiable risk factors for both breast cancer and atrial fibrillation/flutter in women aged 55+. 🔹 Shu Wang, MD, PhD Learn more ➡️ https://ow.ly/5MN250ZohI9